AstraZeneca's Brilique Cleared In NICE's Initial Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.